Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IOVA |
---|---|---|
09:32 ET | 36563 | 9.73 |
09:34 ET | 17405 | 9.66 |
09:36 ET | 5369 | 9.7419 |
09:38 ET | 17532 | 9.74 |
09:39 ET | 19212 | 9.8 |
09:41 ET | 16845 | 9.77 |
09:43 ET | 16695 | 9.81 |
09:45 ET | 31881 | 9.685 |
09:48 ET | 14524 | 9.685 |
09:50 ET | 8474 | 9.605 |
09:52 ET | 40115 | 9.63 |
09:54 ET | 4757 | 9.625 |
09:56 ET | 39436 | 9.61 |
09:57 ET | 28575 | 9.5942 |
09:59 ET | 31338 | 9.6098 |
10:01 ET | 18231 | 9.645 |
10:03 ET | 6296 | 9.68 |
10:06 ET | 5402 | 9.655 |
10:08 ET | 4420 | 9.6635 |
10:10 ET | 12045 | 9.67 |
10:12 ET | 8571 | 9.66 |
10:14 ET | 10475 | 9.645 |
10:15 ET | 23437 | 9.605 |
10:17 ET | 10084 | 9.61 |
10:19 ET | 31094 | 9.675 |
10:21 ET | 14928 | 9.7 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Iovance Biotherapeutics Inc | 3.0B | -5.8x | --- |
Xenon Pharmaceuticals Inc | 3.1B | -14.9x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Geron Corp | 2.7B | -12.2x | --- |
Apogee Therapeutics Inc | 3.3B | -25.0x | --- |
MoonLake Immunotherapeutics | 3.3B | -56.8x | --- |
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $32.8M |
Shares Outstanding | 303.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.60 |
EPS | $-1.68 |
Book Value | $2.28 |
P/E Ratio | -5.8x |
Price/Sales (TTM) | 90.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,401.36% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.